Pharmicell Co: Revenue and profit surged on Bio-Chemical growth, with robust cash flow and new plant investment

About this update from Pharmicell Co., Ltd

Revenue and net income rose sharply year-over-year, driven by strong Bio-Chemical sales and improved margins. Major investments in new production capacity and ongoing clinical trials support future growth, while risk management focuses on FX and credit exposures.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmicell Co., Ltd